AKRO
Akero Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website akerotx.com
- Employees(FY) 51
- ISIN US00973Y1082
Performance
-4.23%
1W
-8.58%
1M
-4.64%
3M
+37.95%
6M
-14.69%
YTD
-56.97%
1Y
Profile
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Investment Analysis Report: AKRO
Overview
AKRO is a pharmaceutical company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has shown significant growth in its enterprise value over the past three years, with a market capitalization of $1.16 billion. In this report, we will conduct a com...
Technical Analysis of AKRO 2024-05-10
Overview:
In analyzing the technical indicators for AKRO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-15 09:26
- 2024-05-12 21:01
- 2024-05-10 07:45
- 2024-05-10 07:00
- 2024-05-10 01:54
- 2024-05-09 19:00
- 2024-05-08 07:00
- 2024-05-07 19:00
- 2024-04-30 08:00
- 2024-04-29 20:00
- 2024-04-21 18:00
- 2024-03-20 13:32
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks(Insider Monkey)
- 2024-03-20 01:32
- 2024-03-20 00:58
- 2024-03-18 07:00
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That(The Wall Street Journal)
- 2024-03-15 09:30
- 2024-03-14 10:40
- 2024-03-08 16:02
- 2024-03-08 03:02
- 2024-03-07 16:01
- 2024-03-07 03:01
- 2024-03-06 23:54
- 2024-03-05 21:13
- 2024-03-05 14:12
- 2024-03-05 08:13
- 2024-03-05 01:12
- 2024-03-04 16:21
- 2024-03-04 16:04
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment(Investor's Business Daily)
- 2024-03-04 12:30
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs(The Wall Street Journal)
- 2024-03-04 11:59
Page 1 of 6
previousnext